


# Patient Experiences in Medicare: National Psoriasis Foundation 2018 Advocacy Survey

Psoriasis (PsO) and psoriatic arthritis (PsA) are chronic, immune-mediated diseases that require a combination of life-long care and treatments to be well managed. While there are effective treatment options, a 2018 survey by the National Psoriasis Foundation found that access remains a problem.

## Medicare Patient Demographics



47% have an annual household income below \$50,000


More than half feel very self-conscious because of their PsO

Over 60% have at least one comorbid condition

Psoriasis (PsO)  
Psoriatic Arthritis (PsA)  
PsO and PsA


## 32% surveyed have Medicare

### Medicare Beneficiary Treatment Types




For PsO and PsA patients, any delay in access to the right treatment can result in increased disease activity, loss of function, and possible irreversible disease progression.

## Medicare Patient Experiences with Cost



Nearly 1 in 3 Medicare beneficiaries who take biologics report a monthly out of pocket cost greater than \$200.




50% of Medicare beneficiaries experience financial strain due to the cost of biologics.



1 in 5 have had a change in out of pocket costs that has impacted their ability to access treatment.


## Access to Biologics for Medicare Beneficiaries



31% receive their biologics through Medicare Part B, meaning they are physician-administered.\*

I'm 70% less likely to receive a biologic if I don't have Medicare Part D Low-Income Subsidies or if I'm African American.\*

I take an average of 4.7 medications in addition to those I take for PsO.\*



\*Source: Junko et al. 2015. Psoriasis in the U.S. Medicare Population. Full article: <https://www.sciencedirect.com/science/article/pii/S0022202X15601592>